REG - Asimilar Group PLC - Statement re Suspension

AsimilarAnnouncement

14/02/2020 16:55

RNS Number : 1166D
Asimilar Group PLC
14 February 2020
 


 
Asimilar Group plc
("Asimilar" or the "Company")
Statement re Suspension
Asimilar Group Plc, the AIM quoted investment company focused on technology opportunities in the fields of big data, machine learning, telematics and the Internet of Things (IoT) notes a press article that states that the Company is to acquire a stake in a Belgium AI company named Sentiance NV ("Sentiance").
The Board confirms that the Company has signed a non-binding term sheet concerning an investment in Sentiance, which, subject to contract, may or may not be considered to be a reverse takeover transaction.  Whilst work continues on this investment, the Company's shares have been suspended pursuant to AIM Rule 40.
The Company's shares will remain suspended until such time as the Company publishes an admission document or discussions in relation to a possible reverse takeover transaction cease.
The Company is continuing to work with Sentiance to finalise binding legal documentation, although there is no guarantee that a formal agreement will be reached.
Further announcements will be made in due course.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
**ENDS**
Enquiries



Asimilar Group plc








John Taylor, Non-Executive Chairman


via Buchanan














Cairn Financial Advisers LLP








Sandy Jamieson, Liam Murray


Tel: +44 20 7213 0880














Peterhouse Capital Limited








Duncan Vasey / Lucy Williams


Tel: + 44 20 7220 9797














Buchanan Communications Limited








Richard Oldworth / Chris Lane


Tel: +44 (0) 20 7466 5000













 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRKKQBQABKDDBD